Miranda J., Lefin N., Beltran J.F., Belén L.H., Tsipa A., JFarias J.G., Zamorano M. (2023) Enzyme engineering strategies for the bioenhancement of L-Asparaginase used as a biopharmaceutical BioDrugs, online ahead of print. ⇒ Abstract
Duan Y., Zhou J., Zhou Z., Zhang E., Yu Y., Krishnan N., Silva-Ayala D., Fang R.H., Griffiths A., Gao W., Zhang L. (2023) Extending the in vivo Residence time of macrophage nembrane-coated nanoparticles through genetic modification Small., e2305551 ⇒ Abstract
Maejima A., Suzuki S., Makabe K., Kumagai I., Asano R. (2023) Incorporation of a repeated polypeptide sequence in therapeutic antibodies as a universal masking procedure: A case study of T cell-engaging bispecific antibodies. N. Biotechnol. 77, 80-89. ⇒ Abstract
Bonnard T., Jayapadman A., Putri J. A., Cui J., Ju Y., Carmichael C., Angelovich T. A., Cody S. H., French S., Pascaud K., Pearce H. A., Jagdale S., Caruso F., Hagemeyer C. E. (2023) Low-fouling and biodegradable protein-based particles for thrombus imaging. ACS Nano.12, 6988-6996. ⇒ Abstract
Sevieri M., Pinori M., Chesi A., Bonizzi A., Smegaitia L., Truffi M., Morasso C., Corsi F., Mazzucchelli S. (2023) Novel bioengineering strategies to improve bioavailability and in vivo circulation of H-ferritin nanocages by surface functionalization. ACS Omega ⇒ Abstract
Najjari A., Shahbazmohammadi H., Nojoumi S. A., Omidinia E. (2023) PASylated Urate Oxidase Enzyme: Enhancing Biocatalytic Activity, Physicochemical Properties, and Plasma Half-Life. ACS Omega ⇒ Abstract
Gruenbach M., Muller C. K. S., Schlaepfer E., Baroncini L., Russenberger D., Kadzioch N. P., Escher B., Schlapschy M., Skerra A., Bredl S., Speck R. F. (2022) cART restores transient responsiveness to IFN type 1 in HIV-infected humanized mice. J. Virol.96, e0082722. ⇒ Abstract
Zhang Q., Li S., Wu W., Xia X., Zhang J. (2022) PASylation improves pharmacokinetic of liposomes and attenuates anti-PEG IgM production: An alternative to PEGylation. Nanomedicine 47, 102622⇒ Abstract
Stigler L., Köhler A., Koller M., Job L., Escher B., Potschka H., Thiermann H., Skerra A., Worek F., Wille T. (2021) Post-VX exposure treatment of rats with engineered phosphotriesterases. Arch. Toxicol. 96, 571–583. ⇒ Abstract
Peplau, E., De Rose, F., Eichinger, A., Reder S., Mittelhäuser M., Scafetta G., Schwaiger M., Weber W.A., Bartolazzi A., D’Alessandria C., Skerra A. (2021) Effective rational humanization of a PASylated anti-galectin-3 Fab for the sensitive PET imaging of thyroid cancer in vivo. Sci. Rep. 11, 7358. ⇒ Abstract
Eskandarpour M., Chen Y.H., Nunn M.A., Coupland S.E., Weston-Davies W., Calder V.L. (2021) Leukotriene B 4 and Its Receptor in Experimental Autoimmune Uveitis and in Human Retinal Tissues: Clinical Severity and LTB 4 Dependence of Retinal Th17 Cells. Am. J. Pathol. 191, 320-334. ⇒ Abstract
Brandl F., Busslinger S., Zangemeister-Wittke U., Plückthun A. (2020) Optimizing the anti-tumor efficacy of protein-drug conjugates by engineering the molecular size and half-life. J. Control Release 327, 86-197. ⇒ Abstract
Somayeh Mazaheri S., Talebkhan Y., Mahboudi F., Nematollahi L., Cohan R.A., Ardakani E.M., Bayat E., Sabzalinejad M., Sardari S., Torkashvand F. (2020) Improvement of Certolizumab Fab’ properties by PASylation technology. Sci. Rep. 10:18464. ⇒ Abstract
Escher B., Köhler A., Job L., Worek F., Skerra A. (2020) Translating the Concept of bispecific antibodies to engineering heterodimeric phosphotriesterases with broad organophosphate substrate recognition. Biochemistry 59, 4395-4406. ⇒ Abstract
Peplau E., De Rose F., Reder S., Mittelhaeuser M., Scafetta G., Schwaiger M., Weber W.A., Bartolazzi A., Skerra A., D’Alessandria C. (2020) Development of a chimeric Fab directed against human galectin-3 and validation as an immune-PET tracer for the sensitive in vivo imaging of thyroid cancer. Thyroid 30, 1314-1326. ⇒ Abstract
Bourdeaux F., Kopp Y., Lautenschläger J., Gößner I., Besir H., Vabulas R.M. and Grininger M. (2020) Dodecin as carrier protein for immunizations and bioengineering applications. Sci. Rep. 10:13297. ⇒ Abstract
Tesarova B., Dostalova S., Smidova V., Goliasova Z., Skubalova Z., Michalkova H., Hynek D., Michalek P., Polanska H., Vaculovicova M., Hacek J., Eckschlager T., Stiborova M., Pires .S., Neves A.R.M., Abrantes A.M., Rodrigues T., Matafomei P., Botelhog M.F., Teixeira P., Mendes F., Heger Z. (2020) Surface-PASylation of ferritin to form stealth nanovehicles enhances in vivo therapeutic performance of encapsulated ellipticine. Applied Materials Today 18, 100501. ⇒ Abstract
Shamloo A., Rostami P., Mahmoudi A. (2020) PASylation enhances the stability, potency and plasma half-life of interferon α-2a: a molecular dynamics simulation. Biotechnol. J. 15:e1900385 ⇒ Abstract
Deuschle F.C., Morath V., Schiefner A., Brandt C., Ballke S., Reder S., Steiger K., Schwaiger M., Weber W., Skerra A.(2020) Development of a high affinity Anticalin® directed against human CD98hc for theranostic applications. Theranostics 10, 2172-2187. ⇒ Abstract
Eggenstein E., Richter A., Skerra A. (2020). FluoroCalins: engineered lipocalins with novel binding functions fused to a fluorescent protein for applications in biomolecular imaging and detection. Protein Eng. Des. Sel. 32, 289-296. ⇒ Abstract
Brandl F., Merten H., Zimmermann M., Béhé M., Zangemeister-Wittke U., Plückthun A. (2019). Influence of size and charge of unstructured polypeptides on pharmacokinetics and biodistribution of targeted fusion proteins. J. Control. Release 307, 379-392. ⇒ Abstract
Sezin T., Murthy S., Attah C., Seutter M., Holtsche M.M., Hammers C.M., Schmidt E., Meshrkey F., Mousavi S., Zillikens D., Nunn M.A., Sadik C.D. (2019) Dual inhibition of complement factor 5 and leukotriene B4 synergistically suppresses murine pemphigoid disease. JCI Insight 4, e128239. ⇒ Abstract
Link
Krishnamurthy S., Muthukumaran P., Jayakumar M.K.G., Lisse D., Masurkar N.D., Xu C., Chan J.M., Drum C.L. (2019) Surface protein engineering increases the circulation time of a cell membrane-based nanotherapeutic. Nanomedicine 18, 169-178. ⇒ Abstract
Link
Aghaabdollahian S., Ahangari Cohan R., Norouzian D., Davami F., Asadi Karam M.R., Torkashvand F., Vaseghi G., Moazzami R., Latif Dizaji S. (2019) Enhancing bioactivity, physicochemical, and pharmacokinetic properties of a nano-sized, anti-VEGFR2 Adnectin, through PASylation technology. Sci. Rep. 9, 2978. ⇒ Abstract
Gulati N. M., Stewart P. L., Steinmetz N. F. (2018) Bioinspired shielding strategies for nanoparticle drug delivery applications. Mol. Pharm.
15, 2900-2909⇒ Abstract
Khodabakhsh F., Norouzian D., Vaziri B., Ahangari Cohan R., Sardari S., Mahboudi F., Behdani M., Mansouri K., Mehdizadeh A. (2018) Development of a novel nano-sized anti-VEGFA nanobody with enhanced physicochemical and pharmacokinetic properties. Artif. Cells Nanomed Biotechnol. 46, 1402-1414. ⇒ Abstract
Hoffmann K., Milech N., Juraja S.M., Cunningham P.T., Stone S.R., Francis R.W., Anastasas M., Hall C.M., Heinrich T., Bogdawa H.M., Winslow S., Scobie M.N., Dewhurst R.E., Florez L., Ong F., Kerfoot M., Champain D., Adams A.M., Fletcher S., Viola H.M., Hool L.C., Connor T., Longville B.A.C., Tan Y.F., Kroeger K., Morath V., Weiss G.A., Skerra A., Hopkins R.M., Watt P.M. (2018) A platform for discovery of functional cell-penetrating peptides for efficient multi-cargo intracellular delivery. Sci. Rep. 8, 12538. ⇒ Abstract
Friedrich L., Kornberger P., Mendler C.T., Multhoff G., Schwaiger M., Skerra A. (2018) Selection of an Anticalin® against the membrane form of Hsp70 via bacterial surface display and its theranostic application in tumour models. Biol. Chem. 14, 235-252. ⇒ Abstract
Ahmadpour S., Hosseinimehr S. J. (2018) PASylation as a powerful technology for improving the pharmacokinetic properties of biopharmaceuticals. Curr. Drug Deliv. 15, 331-341. ⇒ Abstract
TESAŘOVÁ B., DOSTÁLOVÁ S., HYNEK D., ADAM V., HEGER Z. (2017) Surface PEGylation and PASylation to regulate nanoparticle interactions with biological environment. MendelNet, 937-942⇒ Abstract
Zvonova E. A., Ershov A. V., Ershova O.A., Sudomoina M. A., Degterev M. B., Poroshin G. N., Eremeev A. V., Karpov A. P., Vishnevsky A. Y., Goldenkova-Pavlova I. V., Petrov A. V., Ruchko S. V., Shuster A. M. (2017) PASylation technology improves recombinant interferon-β1b solubility, stability, and biological activity. Appl. Microbiol. Biotechnol. 101, 1975-1987. ⇒ Abstract
Hedayati M. H., Norouzian D., Aminian M., Teimourian S., Ahangari Cohan R., Sardari S., Khorramizadeh M. R. (2017) Molecular design, expression and evaluation of PASylated human recombinant erythropoietin with enhanced functional properties. Protein J. ⇒ Abstract
Harder M. J., Kuhn N., Schrezenmeier H., Höchsmann B., von Zabern I., Weinstock C., Simmet T., Ricklin D., Lambris J. D., Skerra A., Anliker M., Schmidt C. Q. (2016) Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood ⇒ Abstract
Zelikin A.N., Ehrhardt C. and Healy A.M. (2016) Materials and methods for delivery of biological drugs. Nat. Chem. 8, 997-1007. ⇒ Abstract
Lerchner A., Daake M., Jarasch A., Skerra A. (2016) Fusion of an alcohol dehydrogenase with an aminotransferase using a PAS linker to improve coupled enzymatic alcohol-to-amine conversion. Protein Eng. Des. Sel. 29, 557-562. ⇒ Abstract
Mendler C. T., Feuchtinger A., Heid I., Aichler M., D’Alessandria C., Pirsig S., Blechert B., Wester H. J., Braren R., Walch A., Skerra A., Schwaiger M. (2016) Tumor uptake of anti-CD20 Fabs depends on tumor perfusion. J. Nucl. Med. 57, 1971-1977. ⇒ Abstract
Chhabra K. H., Adams J. M., Jones G. L. , Yamashita M., Schlapschy M., Skerra A., Rubinstein M. and Low M. J. (2016) Reprogramming the body weight set point by a reciprocal interaction of hypothalamic leptin sensitivity and Pomc gene expression reverts extreme obesity. Mol. Metab. 5, 869–881. ⇒ Abstract
Bolze F., Bast A., Mocek S., Morath V., Yuan D., Rink N., Schlapschy M., Zimmermann A., Heikenwalder M., Skerra A., Klingenspor M. (2016) Treatment of diet-induced lipodystrophic C57BL/6J mice with long-acting PASylated leptin normalises insulin sensitivity and hepatic steatosis by promoting lipid utilisation. Diabetologia 59, 2005-2012. ⇒ Abstract
Fracasso G., Falvo E., Colotti G., Fazi F., Ingegnere T., Amalfitano A., Doglietto G.B., Alfieri S., Boffi A., Morea V., Conti G., Tremante E., Giacomini P., Arcovito A., Ceci P. (2016) Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness. J. Control. Release 239, 10-18. ⇒ Abstract
Falvo E., Tremante E., Arcovito A., Papi M., Elad N., Boffi A., Morea V., Conti G., Toffoli G., Fracasso G., Giacomini P., Ceci P. (2016) Improved doxorubicin encapsulation and pharmacokinetics of ferritin-fusion protein nanocarriers bearing proline, serine, and alanine elements. Biomacromolecules 17, 514-522. ⇒ Abstract